These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24201100)

  • 1. Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.
    Anda T; Honda M; Ishihara T; Kamei T
    Neurol Med Chir (Tokyo); 2014; 54(4):327-30. PubMed ID: 24201100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
    Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unusual case of "sterile" abscess within low-grade meningioma during anti androgenic therapy and LH-releasing hormone agonist treatment for prostate cancer.
    Fabbri VP; Asioli S; Palandri G
    Clin Neurol Neurosurg; 2020 Sep; 196():105993. PubMed ID: 32563976
    [No Abstract]   [Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma.
    Lee KL; Terris MK
    Urology; 2003 Aug; 62(2):351. PubMed ID: 12893358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
    Akaza H; Homma Y; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Ohashi Y; Aso Y
    Jpn J Clin Oncol; 2000 Mar; 30(3):131-6. PubMed ID: 10798540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B
    Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
    Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy Plus GnRH Analogue
    Buwenge M; Deodato F; Macchia G; Siepe G; Zhao X; Valicenti RK; Cilla S; Alitto AR; Ntreta M; Bisello S; Mantini G; Valentini V; Morganti AG; Cammelli S
    Anticancer Res; 2019 Nov; 39(11):6373-6378. PubMed ID: 31704870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 15. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 16. Granulomas induced by subcutaneous injection of leuprorelin acetate.
    Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
    J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
    Salvador C; Planas J; Raventós C; Ropero J; Placer J; López MA; Morote J
    Actas Urol Esp; 2012 Apr; 36(4):205-9. PubMed ID: 22178349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer.
    Ebara S; Manabe D; Kobayashi Y; Tanimoto R; Saika T; Nasu Y; Saito S; Satoh T; Miki K; Hashine K; Kumon H
    Acta Med Okayama; 2007 Dec; 61(6):335-40. PubMed ID: 18183078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Crawford ED
    Urology; 1995 Dec; 46(6):899-901. PubMed ID: 7502440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.